title: Gastrointestinal stromal tumors and leiomyosarcomas.
abstract: Only recently has gastrointestinal stromal tumor (GIST) been recognized as the most frequent GI mesenchymal neoplasm. Prior to the use of KIT staining, most GI stromal tumors were identified as leiomyosarcoma (LMS). For primary GIST, surgery remains the principal treatment and adjuvant imatinib may improve outcomes. Multimodality therapy may also be effective in patients with metastatic GIST. In this review, we summarize the epidemiology, clinicopathologic features, natural history, and clinical management of LMS and GIST.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
authors.forename: Steven C
authors.initials: SC
authors.lastname: Katz
authors.forename: Ronald P
authors.initials: RP
authors.lastname: DeMatteo
mesh_terms: D000465:Algorithms; D003131:Combined Modality Therapy; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007890:Leiomyosarcoma / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D011379:Prognosis